Create a beautiful paper ice cream cone decoration with this simple and fun papercraft project for all skill levels.

This week on Film Riot, we learn some cool sci-fi visual effects using Adobe After Effects. With a new space gun prop from ...

ROANOKE, Va. (WDBJ) - Bill is a Vietnam era veteran who served in the U.S. Army as an electronic instructor on the then secret HAWK surface-to-air missile system at the Ordinance Guided Missile School ...

NEW YORK, June 6 (Reuters) - Pfizer (PFE.N), opens new tab presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its purchase of Metsera last year ...

PFE trades at just 8x forward earnings while paying a near-7% dividend yield, and the five-year base case model targets $49. Pfizer's Berobenatide GLP-1 posted 16% weight loss at 32 weeks with no ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

When you boil it all down, the board of directors decides on a company's dividend policy. It is entirely up to this group. Obviously, they don't work in a vacuum. The board consults with a company's ...

In a 32-week extension of its phase 2b VESPER-1 study, patients with obesity or overweight who escalated from placebo to a 2.4 mg weekly dose of berobenatide achieved a non-placebo-adjusted weight ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 clinical ...

Pfizer Inc. is pulling back the curtain on its obesity ambitions, releasing new data on an experimental weight-loss shot and outlining a strategy to claw its way into a leadership position in the ...

June 15 - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country. Pharmaceutical companies including Eli Lilly ...

The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers.